title: Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections.
abstract: More than 400,000 primary hip and knee replacement surgeries are performed each year in the United States. From these procedures, approximately 0.5-3% will become infected and when considering revision surgeries, this rate has been found to increase significantly. Antibiotic-resistant bacterial infections are a growing problem in patient care. This in vitro research investigated the antimicrobial potential of the polymer released, broad spectrum, Cationic Steroidal Antimicrobial-13 (CSA-13) for challenges against 5 × 10(8) colony forming units (CFU) of methicillin-resistant Staphylococcus aureus (MRSA). It was hypothesized that a weight-to-weight (w/w) concentration of 18% CSA-13 in silicone would exhibit potent bactericidal potential when used as a controlled release device coating. When incorporated into a polymeric device coating, the 18% (w/w) broad-spectrum polymer released CSA-13 antimicrobial eliminated 5 × 10(8) CFU of MRSA within 8 h. In the future, these results will be utilized to develop a sheep model to assess CSA-13 for the prevention of perioperative device-related infections in vivo.
authors.affiliation: Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA. kristofer.sinclair@hsc.utah.edu
authors.forename: K D
authors.initials: KD
authors.lastname: Sinclair
authors.forename: T X
authors.initials: TX
authors.lastname: Pham
authors.forename: R W
authors.initials: RW
authors.lastname: Farnsworth
authors.forename: D L
authors.initials: DL
authors.lastname: Williams
authors.forename: C
authors.initials: C
authors.lastname: Loc-Carrillo
authors.forename: L A
authors.initials: LA
authors.lastname: Horne
authors.forename: S H
authors.initials: SH
authors.lastname: Ingebretsen
authors.forename: R D
authors.initials: RD
authors.lastname: Bloebaum
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000494:pharmacology*; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D011108:Polymers / Q000737:chemistry*; D016062:Porosity; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control*; D013256:Steroids / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000890:Anti-Infective Agents; D020099:Coated Materials, Biocompatible; D011108:Polymers; D013256:Steroids; C521528:ceragenin CSA-13